Multiple sclerosis (MS) is a debilitating autoimmune disease that currently does not have a cure. It affects around 400,000 people in the United States alone, with symptoms presenting most often between 20 and 40 years of age.
The FDA approval of Glatopa is a big deal for patients being treated for MS, especially since medication costs for this condition are nearing $60,000 a year.
Glatopa will be the first generic multiple sclerosis product approved for use in the United States. It is expected to offer those with MS a more affordable yet high-quality option.
What is multiple sclerosis?
Multiple sclerosis, also known as MS, is an autoimmune disease—this means that your body begins to attack itself. The cause is unknown.
In MS your immune system attacks the protective covering of your nerves, which disrupts communication to your brain as well as other parts of your body.
For more information from The Mayo Clinic on MS click here.
Copaxone is also available in a 40mg/mL injection for use three times weekly, however, this strength has not received generic approval by the FDA yet.
What are the most common side effects?